Veradermics, Inc

Veradermics, Inc ने 11 अगस्त 2026 को क्या बताया

कंपनी की अपनी 8-K रिपोर्ट से।

अर्निंग कॉल

Veradermics, Inc के लिए कोई अर्निंग कॉल ट्रांसक्रिप्ट उपलब्ध नहीं है।

प्रबंधन ने क्या कहा

“In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the program. The positive Phase 2 results from Study ‘207’ marked the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States and increased our conviction in VDPHL01 as a potential treatment for women as we advance toward registration-directed topline data from the now fully enrolled Phase 2/3 Study ‘306’ in the first half of 2027,”

विज्ञप्ति से हूबहू उद्धृत, और तभी दिखाया गया जब रिपोर्ट उसे किसी नामित व्यक्ति से जोड़ती है।

शेयर भाव ने कैसी प्रतिक्रिया दी

विज्ञप्तियाँ बंद होने के बाद या खुलने से पहले आती हैं, इसलिए यह हलचल अगले सत्र की है।

Veradermics, Inc क्या करती है

VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern Exhibit 99.1 hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043.

कंपनी का अपना विवरण, जैसा विज्ञप्ति के अंत में दिया गया है।